-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

Benzinga·10/07/2026 17:01:19
Listen to the news
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.